ASCO 2021 Lung Recap : Lurbinectedin in Small Cell Lung Cancer And The Failed Atlantis Trial [ Video ] .

Treatment With Lurbinectedin And Doxorrubicin Missed The Prespecified End Point of Overall Survival in Patients With Small Cell Lung Cancer Who Progressed After 1 Prior Platinum Therapy .

LUNG CANCER . January 21, 2022 .

Drs. H. Jack West, Joan Schiller, And Isabel Preeshagul Gathered ( Virtually ) To Review Information Presented At ASCO And ESMO for 2021.

For This Series, The Doctors Discuss New Trials For Patients With NSCLC . In This Video, The Doctors Discuss Lurbinectedin in SCLC And The Failed ATLANTIS Trial . 

For More, Please Visit http://cancerGRACE.org/ . To Join The Conversation, Visit https://cancergrace.org/forum .